• Bacteria: Unsung Players in the Tumor Microbiome

    Clinical Research News | How cancer patients will respond to treatment can be anticipated based on their genetics as well as the tumor microenvironment, although one relevant component is often all but dismissed: the tumor microbiota. This is despite an abundance of evidence that a cancer’s microbial community plays a major role not only in therapeutic effects but also in tumor development, progression, and metastasis formation.

    May 20, 2026

  • FDA Conversation on Selective Safety Data Collection

    Clinical Research News | Earlier this month, TransCelerate BioPharma released a summary report focused on selective safety data collection (SSDC) gathered during a joint tabletop exercise convened in late 2025 in collaboration with U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI).

    May 19, 2026

  • 23andMe: How Genetics Contribute to GLP-1 Drug Outcomes

    Clinical Research News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.

    May 13, 2026

  • AI Framework for Differentiating Neurodegenerative Diseases

    Clinical Research News | A team of computational scientists at Lund University (Sweden) have built a deep, joint-learning proteomics model for improving the diagnostic accuracy for a handful of dementia-related conditions which in primary care settings remains challenging due to a shortage of informative biomarkers. Predicting these different but correlated pathologies together with a single blood test would facilitate a differential diagnosis with speed and confidence.

    May 12, 2026

  • Strengthening Patient Recruitment Through Smarter Trial Design

    Clinical Research News | Patient recruitment remains one of the most persistent bottlenecks in clinical research. Issues such as increasing protocol complexity, competition for eligible participants, and growing expectations around diversity are placing ever-greater pressure on study timelines. However, recruitment challenges are often a symptom of earlier decisions; when protocol feasibility is misjudged, or patient realities are not fully considered, recruitment delays become inevitable.

    May 8, 2026

  • The Scope of Things: Bridging Health Equity in Clinical Research

    Clinical Research News | Among the shifting tides around DEI, people are finding creative ways to keep the momentum going for equitable clinical trials. Ramona Burress, co-founder of Onyx Health Collective, and Cassandra O’Neal, founder of Illuminated Arc Consulting, discuss a practical look at health equity in clinical trials in the latest episode of The Scope of Things.

    May 6, 2026

  • Much Progress Needed Planning Research to Consider Sex as a Biological Variable

    Clinical Research News | In 2016, the National Institutes of Health (NIH) introduced a policy requiring grantees to consider sex as a biological variable in their experimental design, analyses, and reporting. Now a team from Northwestern University has assessed progress, highlighting significant room for improvement.

    May 5, 2026

  • Much Progress Needed Planning Research to Consider Sex as a Biological Variable

    Clinical Research News | In 2016, the National Institutes of Health (NIH) introduced a policy requiring grantees to consider sex as a biological variable in their experimental design, analyses, and reporting. Now a team from Northwestern University has assessed progress, highlighting significant room for improvement.

    May 5, 2026

  • Follow the Money: AKT1-Selective Inhibitors, Vision Restoration Treatments, Neurology and Neuropsychiatric Treatments

    Clinical Research News | Terremoto Biosciences advances lead AKT1-selective inhibitor programs through phase 1 clinical development; Ray Therapeutics provides support of late-stage clinical development and commercial readiness for the company’s lead program in retinitis pigmentosa; Tortugas advances its two lead candidates; and more.

    Apr 30, 2026